US Patent

US11633478 — Compositions and kits for Omeprazole suspension

Formulation · Assigned to Azurity Pharmaceuticals Inc · Expires 2039-07-16 · 13y remaining

Vulnerability score 33/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects liquid diluents, formulations, and kits for preparing reconstituted suspensions of omeprazole, a proton pump inhibitor.

USPTO Abstract

Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.

Drugs covered by this patent

Patent Metadata

Patent number
US11633478
Jurisdiction
US
Classification
Formulation
Expires
2039-07-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Azurity Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.